Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment

References

• Gull WW. A case of intermittent haematinuria, with remarks. Guys Hosp Rep. 1866;12:381–392.
   Google Scholar
• Strubling P. Paroxysmale haemoglobinurie [Paroxysmal hemoglobinuria]. Dtsch Med Wochenschr. 1882;8:17. German.
   Google Scholar
• Hijmans van den Berg AA. Ictere hemolytique avec crises hemoglobinuriques. Fragilite globulare [Jaundice hemolysis with crisis. Fragile cells]. Rev Med. 1911;31:63. French.
   Google Scholar
• Crosby WH. Paroxysmal nocturnal hemoglobinuria: a report of a case complicated by an aregenerative (aplastic) crisis. Ann Intern Med. 1953;39:1107–1117.
   Web of Science ®Google Scholar
• Ham TH, Dingle JH. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunologic aspects of the hemolytic mechanism with special reference to serum complement. J Clin Invest. 1939;18:657–672.
   PubMedGoogle Scholar
• Ham TH, Hinz CF Jr, Weisman R Jr. Mechanism of destruction of red blood cells in certain hemolytic conditions. Arch Intern Med. 1956;96:574–592.
   Google Scholar
• Weidmer T, Hall SE, Ortel TL, Kane WH, Rosse WF, Sims PJ. Complement-induced vesiculation and exposure of prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood. 1993;82:1192–1196.
   Web of Science ®Google Scholar
• Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350:552–559.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110:4123–4128.
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008;111:1840–1847.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria; sustained efficacy and improved survival. Blood. 2011;117:6786–6792.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Lewis SM, Bessler M, Luzatto L. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;33:1253–1258.
   Google Scholar
• Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207.
   Web of Science ®Google Scholar
• Pu JJ, Brodsky RA. Paroxysmal nocturnal hemoglobinuria from bench to bedside. Clin Transl Sci. 2011;4:210–224.
   Web of Science ®Google Scholar
• Bessler M, Mason PJ, Hillmen P, et al. Paroxysmal nocturnal hemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J. 1994;13:110–117.
   PubMed Web of Science ®Google Scholar
• Fujioka S, Yamada T. Varying populations of CD59-negative, partly positive and normally positive blood cell in different cell lineages in peripheral blood of paroxysmal nocturnal hemoglobinuria patients. Am J Hematol. 1994;45:122–127.
   PubMed Web of Science ®Google Scholar
• Rollinson S, Richards S, Norfolk D, Bibi K, Morgan G, Hillmen P. Both paroxysmal nocturnal hemoglobinuria type III and paroxysmal type involving II cells can arise from different point mutations the same codon of the PIG-A gene. Blood. 1997;89:3069–3071.
   PubMed Web of Science ®Google Scholar
• Bessler M, Mason PJ, Hillmen P, Luzzatto L. A gene causing partial deficiency of the GPI linked surface proteins (PNH II) in patients with paroxysmal nocturnal hemoglobinuria. Br J Haematol. 1994;87:863–866.
   PubMed Web of Science ®Google Scholar
• Holers VM. Complement and its receptors: new insights into human disease. Annu Rev Immunol. 2014;32:433–459.
   PubMed Web of Science ®Google Scholar
• Amara U, Flierl M, Rittirsch D, et al. Molecular intercommunication between complement and the coagulation systems. J Immunol. 2010;185:5628–5636.
   PubMed Web of Science ®Google Scholar
• Huber-Lung M, Sarna JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement pathway. Nat Med. 2006;12:682–687.
   Web of Science ®Google Scholar
• Landsem A, Nielsen EW, Fure H, et al. C1q inhibitor efficiently inhibits E. coli induced tissue factor mRNA upregulation and monocyte tissue factor expression and coagulation in human whole blood. Clin Exp Immunol. 2013;173:217–229.
   Web of Science ®Google Scholar
• Jaillon S, Bonavita E, Gentile S, et al. The long pentraxin as a key component of humoral innate immunity and a candidate diagnostic for inflammatory disease. Int Arch Allergy Immunol. 2014;165:165–178.
   PubMed Web of Science ®Google Scholar
• Weitz IC, Razavi, P, Rochanda L, et al. Eculizumab results in rapid and sustained decrease in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticles. Thromb Res. 2012;130:130–138.
   Web of Science ®Google Scholar
• Sugimori C, Mochizuki K, Qi Z, et al. Origin and fate of blood cells deficient in glycosylphosphatidylinositol anchored proteins among patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2009;147:102–112.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Papaioannou M, Sica M, et al. Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121:2753–2761.
   PubMed Web of Science ®Google Scholar
• Wang SY, Yang XJ, Wang W, Tian YY, Cao FL, Zhou J. Association analysis of cytokine polymorphisms and plasma level in Northern Chinese Han patients with paroxysmal nocturnal hemoglobinuria. Chin Med J (Engl). 2012;125:1576–1580.
   Web of Science ®Google Scholar
• Zeng W, Miyazato A, Chen G, Kajigaya S, Young NS, Maciejewski JP. Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood. 2006;107:167–176.
   PubMed Web of Science ®Google Scholar
• Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015;373:35–47.
   PubMed Web of Science ®Google Scholar
• Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59-blood cells predicts response to immunosuppressive therapy and prognosis in patients with aplastic anemia. Blood. 2006;107:1308–1314.
   PubMed Web of Science ®Google Scholar
• Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577.
   PubMed Web of Science ®Google Scholar
• de Latour RP, Mary JY, Salanoubat C, et al; French Society of Hematology; French Association of Young Hematologists. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112:3099–3106.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Jang JH, Kim JS, et al. Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. Int J Hematol. 2013;97:749–757.
   PubMed Web of Science ®Google Scholar
• Weitz I, Meyers G, Lamy T, et al. Cross-sectional validation study of patient-reported outcomes in patients with paroxysmal nocturnal haemoglobinuria. Intern Med J. 2013;43:298–307.
   Web of Science ®Google Scholar
• Hill A, Sapsford RJ, Scally A, et al. Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function. Br J Haematol. 2012;158:409–414.
   PubMed Web of Science ®Google Scholar
• Hill A, Rother RP, Wang X, et al. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2010;149:414–425.
   PubMed Web of Science ®Google Scholar
• Louwes H, Vellenga E, de Wolf JT. Abnormal platelet adhesion on abdominal vessels in a symptomatic patients with paroxysmal nocturnal hemoglobinuria. Ann Hematol. 2001;80:573–576.
   Web of Science ®Google Scholar
• Clark DA, Butler SA, Braren V, Hartmann RC, Jenkins DE Jr. The kidneys in paroxysmal nocturnal hemoglobinuria. Blood. 1981;57:83–89.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Elebute M, Kelly R, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2010;85:553–559.
   PubMed Web of Science ®Google Scholar
• Le XF, Yang TY, Yang XY, Wang XM. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J (Engl). 1990;103:885–889.
   PubMed Web of Science ®Google Scholar
• Nafa K, Bessler M, Mason P, et al. Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis. Haematologica. 1996;81:540–542.
   Web of Science ®Google Scholar
• Gostynski M, Engelter S, Papa S, Ajdacic-Gross V, Gutzwiller F, Lyrer P. Incidence of first-ever ischemic stroke in the Canton Basle-City, Switzerland: a population-based study 2002/2003. J Neurol. 2006;253:86–91.
   Web of Science ®Google Scholar
• Almeida AM, Murakami Y, Baker A, et al. Targeted therapy for inherited GPI deficiency. N Engl J Med. 2007;356:1641–1647.
   PubMed Web of Science ®Google Scholar
• Hugel B, Socié G, Vu T, et al. Elevated circulating microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia. Blood. 1999;93:3451–3456.
   PubMed Web of Science ®Google Scholar
• Liebman HA, Feinstein DI. Thrombosis in patients with paroxysmal nocturnal hemoglobinuria is associated with markedly elevated plasma levels of leucocyte derived tissue bearing microparticles. Thromb Res. 2003;111:235–238.
   Web of Science ®Google Scholar
• Simak J, Holada K, Risitano AM, Zivny JH, Young NS, Vostal JG. Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2004;125:804–813.
   PubMed Web of Science ®Google Scholar
• Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10 Suppl 17):1–12.
   Google Scholar
• Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. Advances in understanding of the pathogenesis of aHUS and HELLP. Br J Haematol. 2008;143:336–348.
   PubMed Web of Science ®Google Scholar
• Tichaczek-Goska D. Deficiencies and excessive human complement system activation in disorders of multifarious etiology. Adv Clin Exp Med. 2012;21:105–114.
   Web of Science ®Google Scholar
• Frimat M, Tabarin F, Dimitrov JD, et al. Complement activation by heme as a secondary hit for atypical hemolytic uremic syndrome. Blood. 2013;122:282–292.
   PubMed Web of Science ®Google Scholar
• Helley D, de Latour RP, Porcher R, et al. Evaluation of hemostasis and endothelial function in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Haematologica. 2010;95:574–581.
   PubMed Web of Science ®Google Scholar
• Maroney SA, Mast AE. Expression of tissue factor pathway inhibitor by endothelial cells and platelets. Transfus Apher Sci. 2008;38:9–14.
   Web of Science ®Google Scholar
• Ariëns RA, Alberio G, Moia M, Mannucci PM. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis. Thromb Haemost. 1999;81:203–207.
   PubMed Web of Science ®Google Scholar
• Grünewald M, Siegemund A, Grünewald A, et al. Plasmatic coagulation and fibrinolytic system alterations in PNH: relation to clone size. Blood Coagul Fibrinolysis. 2003;14:685–695.
   PubMed Web of Science ®Google Scholar
• Redecha P, Tilley R, Tencati M, et al. Tissue factor: a link between C5a and neutrophil activation in the antiphospholipid syndrome. Blood. 2007;110:2423–2431.
   PubMed Web of Science ®Google Scholar
• Shao Z, Nishimura T, Leung LL, Morser J. Carboxypeptidase B2 deficiency reveals opposite effects of complement C3a and C5a in a murine polymicrobial sepsis model. J Thromb Haemost. 2015;13:1090–1102.
   Web of Science ®Google Scholar
• Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008;6:1517–1524.
   PubMed Web of Science ®Google Scholar
• Del Conde I, Bharwani LD, Dietzen DJ, Pendurthi U, Thiagarajan P, López JA. Microvesicle-associated tissue factor and Trousseau’s syndrome. J Thromb Haemost. 2007;5:70–74.
   PubMed Web of Science ®Google Scholar
• Zwicker JI, Liebman HA, Neuberg D, et al. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009;15:6830–6840.
   PubMed Web of Science ®Google Scholar
• Wojta J, Kaun C, Zorn G, et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100:517–523.
   PubMed Web of Science ®Google Scholar
• Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol. 2006;177:4794–4802.
   PubMed Web of Science ®Google Scholar
• Geddings JE, Mackman N. New players in haemostasis and thrombosis. Thromb Haemost. 2014;111:570–574.
   PubMed Web of Science ®Google Scholar
• Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V; French Study Group for aHUS/C3G. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643–657.
   PubMed Web of Science ®Google Scholar
• Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25:1256–1264.
   PubMed Web of Science ®Google Scholar
• Kelly R, Arnold L, Richards S, et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br J Haematol. 2010;149:446–450.
   Web of Science ®Google Scholar
• Kanakura Y, Ohyashiki K, Shichishima T, et al. Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial. Int J Hematol. 2011;93:36–46.
   PubMed Web of Science ®Google Scholar
• Hill A, Hillmen P, Richards SJ, et al. Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:2559–2565.
   PubMed Web of Science ®Google Scholar
• Kelly RJ, Hill A, Arnold LM, et al. Long term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improvement in survival. Blood. 2011;117:6786–6792.
   PubMed Web of Science ®Google Scholar
• Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370:632–639.
   PubMed Web of Science ®Google Scholar
• Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125:775–783.
   PubMed Web of Science ®Google Scholar
• Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113:4094–4100.
   PubMed Web of Science ®Google Scholar
• Morita Y, Nishimura J, Shimada T, et al. Successful anticoagulant therapy for two pregnant PNH patients, and prospects for the eculizumab era. Int J Hematol. 2013;97:491–497.
   Web of Science ®Google Scholar
• Vekemans MC, Lambert C, Ferrant A, et al. Management of pregnancy in paroxysmal nocturnal hemoglobinuria on long-term eculizumab. Blood Coagul Fibrinolysis. 2015;26:458–463.
   Web of Science ®Google Scholar
• Kelly RJ, Höchsmann B, Szer J, et al. Eculizumab use in pregnancy in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. Epub.
   Google Scholar